Humana and UnitedHealth Group rank among the largest health insurers in the United States, yet they offer investors quite different risk-and-reward profiles. UnitedHealth runs a diversified operation that includes insurance along with its Optum care-services platform, whereas Humana stays much more focused on Medicare Advantage, the private version of the federal Medicare program. Comparing the two helps when weighing a high-momentum turnaround story against a more stable, scaled business model. This analysis looks at recent performance, business drivers, and positioning to gauge which name shows the stronger setup at present.
HUM stands as a leading Medicare Advantage insurer and also runs CenterWell, its senior-focused primary care, pharmacy, and home-health business. After challenges from a drop in its Medicare Star Ratings, Humana has posted one of the stronger rebounds in the sector, with shares rising roughly 70% year-to-date. The improvement stems from better quality scores, with the company reporting a member-weighted Star Rating near 4.17 for the 2027 cycle. Recent results showed revenue growth of about 26% and an adjusted loss narrower than expected, helped by favorable medical-cost trends. Management raised full-year guidance, and early signs from the annual enrollment period look positive. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
UNH is the largest U.S. health insurer by revenue, combining its UnitedHealthcare insurance operations with Optum, which spans pharmacy benefits, care delivery, and analytics. This mix has historically delivered steadier results even when medical costs rise. The stock has advanced about 18% year-to-date, a solid but less dramatic gain than Humana's. In the latest quarter, UnitedHealth beat expectations and lifted its full-year adjusted EPS guidance to at least $20.50, pointing to better cost management. It also carries a higher dividend yield. While its diversification provides some cushion, the company still faces the same regulatory and cost pressures affecting the broader Medicare space.
The main distinction comes down to breadth versus concentration. UNH benefits from earnings spread across insurance and services, which helps smooth volatility and supports its dividend. HUM, being heavily tied to Medicare Advantage, reacts more sharply to shifts in Star Ratings, reimbursement rules, and senior utilization patterns, but that same focus can deliver larger upside when conditions improve. On momentum, HUM leads with a clearer uptrend and catalysts tied to its ratings recovery. Valuation metrics present a mixed picture: Humana's earnings are still expected to decline year-over-year, and its shares trade at a premium on those lower earnings, while UNH shows more conventional growth and a lower price-to-earnings ratio. Both face the proposed CRUSH rule, which could expand audits and repayment requirements across Medicare, Medicaid, and exchange plans.
From what I see in the data, the AI assessment currently favors HUM. Its trend consistency appears stronger, supported by a steadier pattern of higher highs and a more defined catalyst path through Star Ratings improvement and Medicare Advantage membership gains. UNH offers clear advantages in diversification and earnings stability that could matter more over longer periods, yet the near-term momentum and catalyst profile tilt the balance toward Humana. This view reflects current conditions and remains probabilistic rather than a firm prediction.
In my own review process, I often look at Tickeron’s AI Trading Bots to understand how automated strategies are currently positioned across these names and many others. It provides an extra layer of insight into relative strength and strategy performance under today's market conditions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The 10-day RSI Oscillator for HUM moved out of overbought territory on November 17, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 22 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 69%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HUM as a result. In 48 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
The Moving Average Convergence Divergence Histogram (MACD) for HUM turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 29 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
HUM moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +3.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 224 of 350 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
HUM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.711) is normal, around the industry mean (3.520). P/E Ratio (40.612) is within average values for comparable stocks, (126.353). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.008) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company offers health insurance coverage and related services
Industry ManagedHealthCare